Options
Commercialized biomarkers: new horizons in prostate cancer diagnostics
Date Issued
2015-02-24
Date Available
2016-02-24T02:00:11Z
Abstract
Limitations with current clinical tools available for diagnosis and prognosis of prostate cancer (PCa) have resulted in overdiagnosis and costly overtreatment, which is affecting the outcomes and quality of life of men. The biotech industry is investing significant resources into developing more specific biomarkers for PCa detection and patient stratification that would greatly advance the decision-making processes behind PCa management and treatment. In this review, we focus on those biomarkers that have been translated into commercial tests available to clinicians. Since these tests aim to fill specific gaps during the decision-making process of PCa management, we have grouped them based on the clinical question they claim to address, that is, improved PCa screening, false-negative biopsy dilemma, prognostic tests following a positive biopsy and tests predicting relapse/metastases after surgery. We evaluate each test with respect to its development, platform, clinical validation, biomatrix, regulatory approval status and cost.
Sponsorship
European Commission - Seventh Framework Programme (FP7)
Health Research Board
Science Foundation Ireland
Other Sponsorship
Marie Curie (FP-7) Industry-Academia Partnerships and Pathways under the 'FAST-PATH' program
Prostate Cancer Research Consortium
Irish Cancer Society
Type of Material
Journal Article
Publisher
Expert Reviews
Journal
Expert Review of Molecular Diagnostics
Volume
15
Issue
4
Start Page
491
End Page
503
Copyright (Published Version)
2015 Expert Reviews
Language
English
Status of Item
Peer reviewed
This item is made available under a Creative Commons License
File(s)
Owning collection
Scopus© citations
12
Acquisition Date
Apr 16, 2024
Apr 16, 2024
Views
1715
Acquisition Date
Apr 16, 2024
Apr 16, 2024
Downloads
1077
Last Week
1
1
Acquisition Date
Apr 16, 2024
Apr 16, 2024